4 weeks Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?Zacks
Investor focus is likely to be on the sales numbers of LLY’s tirzepatide medicines, Mounjaro and Zepbound.
XInvestor focus is likely to be on the sales numbers of LLY’s tirzepatide medicines, Mounjaro and Zepbound.
X